About this trial

AcceleRET-Lung: A clinical trial to compare a medicine called pralsetinib with standard-of-care chemotherapy treatments in people with non-small cell lung cancer (NSCLC).

Patient Profile

This clinical trial is recruiting people with non-small cell lung cancer (NSCLC) that cannot be removed through surgery or that has spread to other parts of the body.

Where’s this trial being run?

St James’s Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information


Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: AcceleRET-Lung
Number: 20-21
Full Title:

A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer

Principal Investigator: Dr Sinead Cuffe
Type: Industry Sponsored

Hoffmann-La Roche

Recruitment Started: Global: 10th July 2020
Ireland: Yes
Global Recruitment Target: 226
Ireland Recruitment Target: 3